Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

BACKGROUND: HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a novel irreversible epidermal growth factor receptor/HER2 dual tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Changjun, Lin, Yan, Zhou, Yidong, Mao, Feng, Zhu, Hanjiang, Guan, Jinghong, Zhang, Xiaohui, Shen, Songjie, Huang, Xin, Chen, Chang, Yao, Ru, Zhao, Jialin, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359576/
https://www.ncbi.nlm.nih.gov/pubmed/32660609
http://dx.doi.org/10.1186/s12885-020-07143-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359576/
https://www.ncbi.nlm.nih.gov/pubmed/32660609
http://dx.doi.org/10.1186/s12885-020-07143-2

Ejemplares similares